Monday, April 11, 2022 5:44:07 PM
The theme of the discussion is: New Science & Clinical Trials That Will Change Glioblastoma Management in the Next Five Years
By the way, Dr. Steven Brem, Director of Neurosurgery at the University of Pennsylvania, was 1 of the investigators on the DCVax-L Phase III trial, and this is what he said about DCVax-L back in 2019 (go to the 1:52 minute mark):
Recent NWBO News
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
